Tenapanor

Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia[1][2].

Product Specifications

CAS Number

[1234423-95-0]

Product Name Alternative

AZD1722; RDX5791

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Na+/H+ Exchanger (NHE)

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Tenapanor.html

Concentration

10mM

Purity

99.65

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(NCCOCCOCCNS(=O)(C1=CC=CC([C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)=C1)=O)NCCCCNC(NCCOCCOCCNS(=O)(C4=CC=CC([C@@H]5CN(C)CC6=C5C=C(Cl)C=C6Cl)=C4)=O)=O

Molecular Formula

C50H66Cl4N8O10S2

Molecular Weight

1145.05

Precautions

H302, H315, H319, H335

References & Citations

[1]King AJ, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018 Aug 29;10 (456) :eaam6474.|[2]King AJ, et al. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats. Am J Physiol Renal Physiol. 2021 Jan 1;320 (1) :F133-F144.